Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$113.87 USD
-0.68 (-0.59%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.87 USD
-0.68 (-0.59%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.
Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?
by Zacks Equity Research
ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
What's in the Cards for Encompass Health (EHC) in Q3 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.
What's in the Cards for Universal Health (UHS) in Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q3 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Will Rising Costs Hurt HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.
Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag
by Sundeep Ganoria
The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.
Can Growing Visits Aid Teladoc's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
by Zacks Equity Research
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
5 Value Stocks With High Earnings Yield to Boost Your Portfolio
by Rimmi Singhi
Unlock your portfolio value with high earnings yield value stocks like URBN, ADNT, OVV, JAZZ and RNR that will boost your returns.
Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
by Zacks Equity Research
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
by Zacks Equity Research
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.